Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -252.37% is 121% below its 4-year average of -114.28%, around the middle of its 4-year range (-411.27%–-16.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.22% above its 12-month average of -266.28%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -252.37%.
RETURN ON EQUITY (ROE)
-252.37%
RETURN ON EQUITY (ROE) AVG TTM
-266.28%
RETURN ON EQUITY (ROE) AVG 3Y
-149.09%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.22%
CURRENT VS 3Y AVG
-69.28%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
-527.80%
vs the sector median at left
Lifeward Ltd.
Market Cap
$10.57M
Return on Equity (ROE)
-252.37%
TTM Avg
-266.28%
3Y Avg
-149.09%
5Y Avg
N/A
Market Cap
$10.53M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
Market Cap
$10.52M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.43M
Return on Equity (ROE)
-57.34%
TTM Avg
-65.47%
3Y Avg
-124.96%
5Y Avg
28.05%
Market Cap
$10.36M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
Market Cap
$10.84M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$11.08M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$10.06M
Return on Equity (ROE)
N/A
TTM Avg
18596.99%
3Y Avg
9182.42%
5Y Avg
7349.85%
Market Cap
$11.12M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lifeward Ltd. (LFWD) | $10.57M | -252.37% | -266.28% | -149.09% | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.53M | N/A | -22.56% | -244.57% | 3710.91% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A | -43.97% | -160.70% | -188.29% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.43M | -57.34% | -65.47% | -124.96% | 28.05% |
| Caring Brands, Inc. (CABR)vs › | $10.36M | -506.63% | -300.20% | -300.20% | -300.20% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.84M | -177.35% | -89.62% | -75.99% | -59.80% |
| Cerenome, Inc. (CNSY)vs › | $11.08M | -477.54% | -207.60% | 64.51% | -22.91% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | 18596.99% | 9182.42% | 7349.85% |
| BioVie Inc. (BIVI)vs › | $11.12M | -214.92% | -46.13% | -156.76% | -652.77% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $10.01M | -189.76% | -774.75% | -460.85% | -442.56% |
ROE
-252.4%
ROA
-88.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -252.37% |
| 2026-03-31 | -411.27% |
| 2025-12-31 | -236.85% |
| 2025-09-30 | -233.98% |
| 2025-06-30 | -196.94% |
| 2025-03-31 | -149.00% |
| 2024-12-31 | -153.55% |
| 2024-09-30 | -56.95% |
| 2024-06-30 | -64.74% |
| 2024-03-31 | -59.31% |
| 2023-12-31 | -47.59% |
| 2023-09-30 | -42.12% |
| 2023-06-30 | -33.47% |
| 2023-03-31 | -30.76% |
| 2022-12-31 | -28.71% |
| 2022-09-30 | -23.96% |
| 2022-06-30 | -18.95% |
| 2022-03-31 | -16.46% |
